The European Medicines Agency has recommended measures to minimize the risk of cardiovascular problems, cancer and other serious side effects associated with five Janus kinase (JAK) inhibitors that are approved in the EU for chronic inflammatory disorders.
The risk minimization measures apply to Xeljanz (tofacitinib) and Cibinqo (abrocitinib), both from Pfizer, and Jyseleca (filgotinib), Olumiant (baricitinib) and Rinvoq (upadacitinib), from Gilead Sciences/Galapagos, Eli Lilly and AbbVie respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?